Kevin Tang Buys 206,005 Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) CEO Kevin Tang bought 206,005 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were bought at an average price of $15.28 per share, with a total value of $3,147,756.40. Following the completion of the purchase, the chief executive officer owned 13,044,106 shares in the company, valued at approximately $199,313,939.68. The trade was a 1.60% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kevin Tang also recently made the following trade(s):

• On Monday, June 1st, Kevin Tang bought 343,620 shares of Aurinia Pharmaceuticals stock. The shares were bought at an average price of $15.28 per share, with a total value of $5,250,513.60.
• On Friday, May 29th, Kevin Tang bought 264,981 shares of Aurinia Pharmaceuticals stock. The shares were bought at an average price of $15.31 per share, with a total value of $4,056,859.11.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH opened at $15.67 on Thursday. The firm has a market cap of $2.02 billion, a PE ratio of 7.22 and a beta of 1.41. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $15.56 and a two-hundred day simple moving average of $15.25. Aurinia Pharmaceuticals Inc has a 1-year low of $7.28 and a 1-year high of $16.88.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. The business had revenue of $77.71 million during the quarter, compared to analyst estimates of $76.98 million. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. On average, equities analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.25.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AUPH. Arrowstreet Capital Limited Partnership increased its stake in shares of Aurinia Pharmaceuticals by 213.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock worth $37,283,000 after purchasing an additional 2,297,903 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Aurinia Pharmaceuticals by 1,272.5% in the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock worth $16,389,000 after purchasing an additional 1,375,072 shares in the last quarter. Kotler Kevin purchased a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth $19,536,000. Two Sigma Investments LP increased its stake in shares of Aurinia Pharmaceuticals by 728.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock worth $14,819,000 after purchasing an additional 1,179,219 shares in the last quarter. Finally, Man Group plc boosted its holdings in Aurinia Pharmaceuticals by 368.9% in the 4th quarter. Man Group plc now owns 852,671 shares of the biotechnology company’s stock worth $13,600,000 after buying an additional 670,812 shares during the period. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.